How should I manage restless legs syndrome in a patient taking aripiprazole (Abilify) who is experiencing auditory hallucinations and cannot use gabapentin because it is not formulary?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of RLS in a Patient on Abilify with Auditory Hallucinations

You must immediately address the auditory hallucinations from Abilify, as this represents a serious psychiatric adverse effect that takes priority over RLS management, then treat the RLS with pregabalin or IV iron as first-line alternatives to gabapentin.

Critical Priority: Address the Auditory Hallucinations

The auditory hallucinations on Abilify represent a potentially serious adverse psychiatric effect that requires immediate attention. While aripiprazole (Abilify) is FDA-approved for schizophrenia and other psychiatric conditions 1, auditory hallucinations as a side effect suggest either:

  • Worsening of underlying psychiatric condition
  • Paradoxical drug reaction
  • Need for medication adjustment or discontinuation

You must consult with the prescribing psychiatrist immediately before making any changes, as abrupt discontinuation could destabilize the underlying psychiatric condition for which Abilify was prescribed.

The Abilify-RLS Connection

Interestingly, there is emerging evidence that aripiprazole may actually treat RLS rather than cause it. Case reports show aripiprazole (at low doses of 1-4 mg) successfully controlled severe RLS and augmentation symptoms in patients who failed other treatments 2, and it has demonstrated efficacy for antidepressant-induced RLS 3. However, other atypical antipsychotics like olanzapine and risperidone have been reported to cause RLS 4, 5.

Common pitfall: Do not assume the Abilify is causing the RLS without proper evaluation. The RLS may be pre-existing, drug-induced by another medication, or related to iron deficiency.

First-Line RLS Treatment (Since Gabapentin Not Available)

According to the 2025 AASM guidelines, with gabapentin unavailable, you have two strong first-line options 6:

Option 1: Pregabalin (Strong Recommendation)

  • The AASM recommends pregabalin for adults with RLS (strong recommendation, moderate certainty of evidence) 6
  • Pregabalin is in the same α2δ ligand class as gabapentin and has equivalent efficacy
  • Typical dosing: Start 75 mg at bedtime, can titrate up to 300-450 mg as needed
  • This is your best pharmacologic option if formulary-approved

Option 2: IV Iron Therapy (Strong Recommendation)

  • The AASM recommends IV ferric carboxymaltose (strong recommendation, moderate certainty of evidence) 6
  • Check iron parameters first: Ferritin and transferrin saturation
  • Treat if ferritin < 75 ng/mL (aim for >100 ng/mL) or transferrin saturation < 20% 7, 8
  • Alternative IV iron formulations with evidence: low molecular weight iron dextran or ferumoxytol 6
  • Critical point: Iron deficiency is a core pathophysiological driver of RLS, and treating it addresses the underlying problem rather than just symptoms 7

Second-Line Options

If pregabalin and IV iron are not feasible:

Oral Iron Supplementation

  • Ferrous sulfate is suggested by AASM (conditional recommendation, moderate certainty) 6
  • Use when ferritin < 75 ng/mL
  • Less effective than IV iron but more accessible
  • Take with vitamin C to enhance absorption

Extended-Release Opioids

  • The AASM suggests extended-release oxycodone and other opioids (conditional recommendation, moderate certainty) 6
  • Reserve for refractory cases due to addiction potential and regulatory concerns
  • Requires careful patient selection and monitoring

Dipyridamole

  • AASM suggests dipyridamole (conditional recommendation, low certainty) 6
  • However, the World Sleep Society does NOT support this recommendation due to limited global evidence 9
  • Consider only if other options exhausted

What to AVOID

Do NOT use dopamine agonists (pramipexole, ropinirole, rotigotine) as standard treatment 6:

  • The 2025 AASM guidelines represent a major paradigm shift away from dopaminergic agents
  • High risk of augmentation (paradoxical worsening of RLS symptoms) with long-term use 10, 7
  • If used at all, only at lowest doses for short-term use in selected patients who value immediate symptom relief over long-term risks

Do NOT use 6:

  • Clonazepam (suggested against)
  • Valproic acid (suggested against)
  • Carbamazepine (suggested against)
  • Bupropion (suggested against)
  • Cabergoline (strong recommendation AGAINST) 6

Clinical Algorithm

  1. Immediate: Contact prescribing psychiatrist about auditory hallucinations on Abilify
  2. Check iron studies: Ferritin and transferrin saturation
  3. If ferritin < 75 ng/mL: Start IV iron therapy (ferric carboxymaltose preferred) OR oral ferrous sulfate if IV not accessible
  4. If iron adequate: Start pregabalin 75 mg at bedtime, titrate as needed
  5. If pregabalin not formulary: Pursue formulary exception for pregabalin OR gabapentin, emphasizing these are now first-line per 2025 AASM guidelines
  6. If all else fails: Consider extended-release opioids with appropriate safeguards

Key Caveats

  • The auditory hallucinations are the immediate priority and may require Abilify adjustment, which could paradoxically worsen RLS if Abilify was providing some benefit 2, 3
  • Iron therapy works slowly (weeks to months); symptomatic treatment may be needed concurrently
  • The 2025 guidelines represent a fundamental shift: iron and α2δ ligands are now first-line, dopamine agonists are discouraged 7, 8
  • Formulary restrictions should not prevent access to evidence-based first-line therapy; pursue exceptions aggressively

References

Research

Aripiprazole Has Potential Efficacy for Antidepressant-induced Restless Legs Syndrome: A Case Series.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2025

Guideline

treatment of restless legs syndrome and periodic limb movement disorder: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025

Research

The evolving treatment landscape of restless legs syndrome.

Therapeutic advances in neurological disorders, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.